The Use of Integrated and Intelligent Testing Strategies in the Prediction of Toxic Hazard and in Risk Assessment
暂无分享,去创建一个
[1] R. W. Kapp,et al. Toxic Substances Control Act , 2014 .
[2] Zvia Agur,et al. Use of Virtual Patient Populations for Rescuing Discontinued Drug Candidates and for Reducing the Number of Patients in Clinical Trials , 2009, Alternatives to laboratory animals : ATLA.
[3] Michael Balls,et al. A Frame Response to the European Commission Consultation on the Draft Report on Alternative (Non-animal) Methods for Cosmetics Testing: Current Status and Future Prospects — 2010 a , 2010 .
[4] Robert Combes,et al. TGN1412: Time to Change the Paradigm for the Testing of New Pharmaceuticals , 2006, Alternatives to laboratory animals : ATLA.
[5] R. Stewart,et al. Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.
[6] T Seidle,et al. The development of new concepts for assessing reproductive toxicity applicable to large scale toxicological programmes. , 2007, Current pharmaceutical design.
[7] N. Kaplowitz,et al. Drug-induced liver injury. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] Terrance J Kavanagh,et al. Luminescent quantum dots for molecular toxicology. , 2012, Advances in experimental medicine and biology.
[9] P. Watkins,et al. The Application of Metabonomics to Predict Drug‐Induced Liver Injury , 2010, Clinical pharmacology and therapeutics.
[10] Daniel A Casciano,et al. The use of genomics in model in vitro systems. , 2012, Advances in experimental medicine and biology.
[11] Kathryn A Phillips,et al. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. , 2007, Current drug safety.
[12] Saber M Hussain,et al. Toxicity testing of nanomaterials. , 2012, Advances in experimental medicine and biology.
[13] D. Noble. Modeling the Heart--from Genes to Cells to the Whole Organ , 2002, Science.
[14] E. Kunkel. Systems biology in drug discovery , 2004, Nature Biotechnology.
[15] Robert Combes,et al. An Integrated Decision-tree Testing Strategy for Repeat Dose Toxicity with Respect to the Requirements of the EU REACH Legislation , 2008, Alternatives to laboratory animals : ATLA.
[16] K. BéruBé,et al. Alternatives for Lung Research: Stuck between a Rat and a Hard Place , 2011, Alternatives to laboratory animals : ATLA.
[17] Ignazio Grattagliano,et al. Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity , 2009, Current medicinal chemistry.
[18] Judith C. Madden,et al. In silico toxicology : principles and applications , 2010 .
[19] D. L. Chesney. Perspectives on GMP compliance in the production of clinical supplies , 1998 .
[20] M. Miller. Agency , 2010 .
[21] Uwe Marx,et al. Trends in cell culture technology. , 2012, Advances in experimental medicine and biology.
[22] R D Combes,et al. Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[23] B Testa,et al. In silico pharmacology for drug discovery: applications to targets and beyond , 2007, British journal of pharmacology.
[24] S. Cole,et al. Sequences Human Induced Pluripotent Stem Cells Free of Vector and Transgene , 2012 .
[25] Robert Combes,et al. Intelligent Testing Strategies for Chemicals Testing — A Case of More Haste, Less Speed? , 2005, Alternatives to laboratory animals : ATLA.
[26] Robert Combes,et al. In vitro models of inhalation toxicity and disease. The report of a FRAME workshop. , 2009, Alternatives to laboratory animals : ATLA.
[27] N. Thomas. Review Article: High-Content Screening: A Decade of Evolution , 2010, Journal of biomolecular screening.
[28] Michael P Holt,et al. Drug-induced liver injury. , 2010, Handbook of experimental pharmacology.
[29] Carl-Fredrik Mandenius,et al. Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using In Vitro Models Derived from Human Embryonic Stem Cells and Human Cell Lines — A Report on the Vitrocellomics EU-project , 2011, Alternatives to laboratory animals : ATLA.
[30] Michael Balls,et al. Integrated Testing Strategies for Toxicity Employing New and Existing Technologies , 2011, Alternatives to laboratory animals : ATLA.
[31] J. Bailar,et al. Toxicity Testing in the 21st Century: A Vision and a Strategy , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[32] T Hartung,et al. Toward an evidence-based toxicology , 2006, Human & experimental toxicology.
[33] Susanne Bremer,et al. Embryonic stem cells in safety pharmacology and toxicology. , 2012, Advances in experimental medicine and biology.
[34] L Hunt,et al. The Value and Benefits of the International Conference on Harmonisation to Drug Regulatory Authorities: Advancing Harmonization for Better Public Health , 2011, Clinical pharmacology and therapeutics.
[35] Michael Balls,et al. Translation of New Technologies in Biomedicines: Shaping the Road from Basic Research to Drug Development and Clinical Application–and Back Again , 2012 .
[36] Jehyuk Lee,et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells , 2009, Hepatology.
[37] Shayne C. Gad,et al. Preclinical Development Handbook , 2008 .
[38] Krishna Prasad,et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium , 2010, Nature Biotechnology.
[39] Arti Ahluwalia,et al. Engineering Quasi-Vivo in vitro organ models. , 2012, Advances in experimental medicine and biology.
[40] Carol A Marchant,et al. An Expert System Approach to the Assessment of Hepatotoxic Potential , 2009, Chemistry & biodiversity.
[41] Robert Combes,et al. Integrated Decision-tree Testing Strategies for Acute Systemic Toxicity and Toxicokinetics with Respect to the Requirements of the EU REACH Legislation , 2008, Alternatives to laboratory animals : ATLA.
[42] Jonathan Balcombe,et al. Animal Carcinogenicity Studies: 2. Obstacles to Extrapolation of Data to Humans , 2006, Alternatives to laboratory animals : ATLA.
[43] Seth Pettie,et al. Mind the gap , 2006, Nature Reviews Drug Discovery.
[44] Tsun-Po Yang,et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies , 2010, Bioinform..
[45] Xudong Zhang,et al. Medium to high throughput screening: microfabrication and chip-based technology. , 2012, Advances in experimental medicine and biology.
[46] T. Ichisaka,et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.
[47] A. Abate,et al. Ultrahigh-throughput screening in drop-based microfluidics for directed evolution , 2010, Proceedings of the National Academy of Sciences.
[48] Robert D Combes,et al. In silico methods for toxicity prediction. , 2012, Advances in experimental medicine and biology.
[49] Epic Admin. Who we regulate , 2007 .
[50] Andrew Worth,et al. Overcoming Barriers to Validation of Non-animal Partial Replacement Methods/Integrated Testing Strategies: The Report of an EPAA–ECVAM Workshop , 2009, Alternatives to laboratory animals : ATLA.
[51] Oa,et al. Summary of the Toxic Substances Control Act , 2013 .
[52] R. Vasan,et al. Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations , 2006, Circulation.
[53] William M. Lee,et al. Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions , 2005, Toxicologic pathology.
[54] Michael Balls,et al. Translation of new technologies: from basic research to drug discovery and development. , 2008, Current drug discovery technologies.
[55] D. L. Taylor,et al. A Personal Perspective on High-Content Screening (HCS) , 2010, Journal of biomolecular screening.
[56] T. Hartung. Toxicology for the twenty-first century , 2009, Nature.
[57] Robert Combes,et al. Preclinical Drug Development Planning , 2010 .
[58] M. Eileen Dolan,et al. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci , 2010, Proceedings of the National Academy of Sciences.
[59] M. Balls. Chapter 23:Integrated Testing Strategies and the Prediction of Toxic Hazard , 2010 .
[60] Kannan Krishnan,et al. Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment. , 2012, Advances in experimental medicine and biology.
[61] Robert Combes,et al. An Integrated Decision-tree Testing Strategy for Skin Sensitisation with Respect to the Requirements of the EU REACH Legislation , 2007, Alternatives to laboratory animals : ATLA.
[62] Johannes Doehmer. The Use and Value of In Vitro Technologies in Metabolism Studies , 2009, Alternatives to laboratory animals : ATLA.
[63] H. Hogberg,et al. Relevance of in vitro neurotoxicity testing for regulatory requirements: challenges to be considered. , 2010, Neurotoxicology and teratology.
[64] K. Shakesheff,et al. Tissue engineering in the development of replacement technologies. , 2012, Advances in experimental medicine and biology.
[65] S. Ekins,et al. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.
[66] Michael Balls. Modern Alternative Approaches to the Problem of Drug-induced Liver Injury , 2011, Alternatives to laboratory animals : ATLA.
[67] Valérie Zuang,et al. Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010 , 2011, Archives of Toxicology.
[68] Robert Combes,et al. An Integrated Decision-tree Testing Strategy for Eye Irritation with Respect to the Requirements of the EU REACH Legislation , 2008, Alternatives to laboratory animals : ATLA.
[69] Robert Combes,et al. Proposed Integrated Decision-tree Testing Strategies for Mutagenicity and Carcinogenicity in Relation to the EU REACH Legislation , 2007, Alternatives to laboratory animals : ATLA.
[70] M. Daly,et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.
[71] Simon Thomas,et al. Physiologically-based Simulation Modelling for the Reduction of Animal Use in the Discovery of Novel Pharmaceuticals , 2009, Alternatives to laboratory animals : ATLA.
[72] Robert Combes,et al. Integrated Decision-tree Testing Strategies for Environmental Toxicity with Respect to the Requirements of the EU REACH Legislation , 2006, Alternatives to laboratory animals : ATLA.
[73] Christina Grindon,et al. Integrated Testing Strategies for Use in the EU REACH System , 2006, Alternatives to laboratory animals : ATLA.
[74] A. Corrias,et al. Arrhythmic risk biomarkers for the assessment of drug cardiotoxicity: from experiments to computer simulations , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.
[75] Robert Combes,et al. A Scientific and Animal Welfare Assessment of the OECD Health Effects Test Guidelines for the Safety Testing of Chemicals under the European Union REACH System , 2004, Alternatives to laboratory animals : ATLA.
[76] Glyn Stacey,et al. Current developments in cell culture technology. , 2012, Advances in experimental medicine and biology.
[77] Steven K. Gibb. Toxicity testing in the 21st century: a vision and a strategy. , 2008, Reproductive toxicology.
[78] Robert Combes,et al. Integrated Decision-tree Testing Strategies for Developmental and Reproductive Toxicity with Respect to the Requirements of the EU REACH Legislation , 2008, Alternatives to laboratory animals : ATLA.
[79] Robert Combes,et al. An Integrated Decision-tree Testing Strategy for Skin Sensitisation with Respect to the Requirements of the EU REACH Legislation , 2008, Alternatives to laboratory animals : ATLA.
[80] Arun V Holden. Development and Application of Human Virtual Excitable Tissues and Organs: From Premature Birth to Sudden Cardiac Death , 2010, Alternatives to laboratory animals : ATLA.
[81] Aniruddh Solanki,et al. A Step Closer to Complete Chemical Reprogramming for Generating iPS Cells , 2010, Chembiochem : a European journal of chemical biology.
[82] Thomas Hartung,et al. The value of alternative testing for neurotoxicity in the context of regulatory needs. , 2006, Environmental toxicology and pharmacology.
[83] Robert Combes,et al. Toxicity testing: creating a revolution based on new technologies. , 2005, Trends in biotechnology.
[84] J. Valentin,et al. An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk , 2010, British journal of pharmacology.
[85] 山上 鋭享. Globally Harmonized System of Classification and Labelling of Chemicals (GHS) 化学品の分類および表示に関する世界調和システム , 2007 .
[86] Christina Grindon,et al. Integrated Decision-tree Testing Strategies for Skin Corrosion and Irritation with Respect to the Requirements of the EU REACH Legislation , 2007, Alternatives to laboratory animals : ATLA.
[87] Weida Tong,et al. FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.